What is Zacks Research's Forecast for PCRX FY2024 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Stock analysts at Zacks Research increased their FY2024 earnings estimates for Pacira BioSciences in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.60 per share for the year, up from their prior estimate of $2.36. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.32 per share. Zacks Research also issued estimates for Pacira BioSciences' Q2 2025 earnings at $0.58 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.61 EPS and FY2026 earnings at $2.64 EPS.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group boosted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Barclays reduced their price objective on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a "buy" rating and issued a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada raised their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $23.50.

Pacira BioSciences Price Performance

PCRX traded up $0.01 during trading on Monday, reaching $19.87. 702,910 shares of the stock were exchanged, compared to its average volume of 851,390. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The company has a market capitalization of $917.40 million, a price-to-earnings ratio of -9.78 and a beta of 0.80. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $35.95. The business's 50 day moving average price is $17.27 and its two-hundred day moving average price is $18.97.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently made changes to their positions in PCRX. Innealta Capital LLC acquired a new stake in Pacira BioSciences during the 2nd quarter valued at $50,000. nVerses Capital LLC increased its position in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after acquiring an additional 1,600 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $113,000. Canada Pension Plan Investment Board acquired a new position in shares of Pacira BioSciences in the second quarter worth about $140,000. Finally, Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences in the third quarter valued at about $98,000. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.